ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FDMT 4D Molecular Therapeutics Inc

25.28
-0.11 (-0.43%)
Last Updated: 09:10:15
Delayed by 15 minutes

Period:

Draw Mode:

Volume 27,299
Bid Price 25.24
Ask Price 25.32
News -
Day High 25.36

Low
9.44

52 Week Range

High
36.25

Day Low 24.93
Share Name Share Symbol Market Stock Type
4D Molecular Therapeutics Inc FDMT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.11 -0.43% 25.28 09:10:15
Open Price Low Price High Price Close Price Previous Close
25.31 24.93 25.36 25.39
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
435 27,299 US$ 25.26 US$ 689,563 - 9.44 - 36.25
Last Trade Type Quantity Price Currency
09:10:32 1 US$ 25.31 USD

4D Molecular Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.26B 49.78M - 20.72M -100.84M -2.03 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

4D Molecular Therapeutics News

Date Time Source News Article
5/01/202407:00GlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual Meeting
3/28/202407:00GlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and..
3/04/202407:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor Conferences
2/29/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/29/202416:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
2/29/202415:12Edgar (US Regulatory)Form 8-K - Current report
2/29/202415:05GlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and..
2/21/202416:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/14/202419:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202415:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202407:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/12/202420:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No FDMT Message Board. Create One! See More Posts on FDMT Message Board See More Message Board Posts

Historical FDMT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week23.5026.5922.7524.27427,7371.787.57%
1 Month28.1729.26522.7526.03489,597-2.89-10.26%
3 Months27.5036.2522.7528.38797,934-2.22-8.07%
6 Months10.8336.259.7326.25802,22714.45133.43%
1 Year18.7736.259.4422.96609,8696.5134.68%
3 Years39.3739.375.3220.36402,938-14.09-35.79%
5 Years40.0055.115.3221.49375,659-14.72-36.80%

4D Molecular Therapeutics Description

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Your Recent History

Delayed Upgrade Clock